The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial
Open accessAbstract
Background and Aims: To report results from VISIBLE 2, a randomised, double-blind, placebo-controlled, phase 3 trial evaluating a new subcutaneous [SC] vedolizumab formulation as maintenance treatment in adults with moderately to severely active Crohn’s disease [CD]. Methods: Following open-label vedolizumab 300 mg intravenous induction therapy at Weeks 0 and 2, Week 6 clinical responders (≥70-point decrease in CD Activity Index [CDAI] score from baseline) were randomised 2:1 to receive double-blind maintenance vedolizumab 108 mg SC or placebo every 2 weeks until Week 50. Assessments at Week 52 included clinical remission [primary endpoint; CDAI ≤150], enhanced clinical response [≥100-point decrease in CDAI from baseline], corticosteroid-free clinical remission among patients using a corticosteroid at baseline, clinical remission in anti-tumour necrosis factor [anti-TNF]-naïve patients, and safety. Results: Following vedolizumab intravenous induction, 275 patients were randomised to vedolizumab SC and 135 to placebo maintenance. At Week 52, 48.0% of patients receiving vedolizumab SC versus 34.3% receiving placebo were in clinical remission [p = 0.008]. Enhanced clinical response at Week 52 was achieved by 52.0% versus 44.8% of patients receiving vedolizumab SC versus placebo, respectively [p = 0.167]. At Week 52, 45.3% and 18.2% of patients receiving vedolizumab SC and placebo, respectively, were in corticosteroid-free clinical remission, and 48.6% of anti-TNF-naïve patients receiving vedolizumab SC and 42.9% receiving placebo were in clinical remission. Injection site reaction was the only new safety finding observed for vedolizumab SC [2.9%]. Conclusions: Vedolizumab SC is an effective and safe maintenance therapy in patients with CD who responded to two infusions of vedolizumab intravenous induction therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Hawthorne effect
Sedgwick, P., & Greenwood, N. (2015) · BMJ · doi:10.1136/bmj.h4672 · Cited by 824
Cited by
ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
Gordon, H., Minozzi, S., Kopylov, U., Verstockt, B., Chaparro, M., Buskens, C., Warusavitarne, J., Agrawal, M., Allocca, M., Atreya, R., et al. (2024) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjae091 · Cited by 388
Self-citationUlcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments
Wangchuk, P., Yeshi, K., & Loukas, A. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.08.003 · Cited by 333
Singh, S., Murad, M. H., Fumery, M., Sedano, R., Jairath, V., Panaccione, R., Sandborn, W. J., & Ma, C. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00312-5 · Cited by 298
Self-citationMagro, F., Moreira, P. L., Catalano, G., Alves, C., Roseira, J., Estevinho, M. M., Silva, I., Dignass, A., Peyrin‐Biroulet, L., Danese, S., et al. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12366 · Cited by 30
Self-citation
Metadata
- Authors
- Vermeire, S., D’Haens, G., Baert, F., Danese, S., Kobayashi, T., Loftus, E. V., Bhatia, S., Agboton, C., Rosario, M., Chen, C., Zhang, W., Kisfalvi, K., & Sandborn, W. J.
- Venue
- Journal of Crohn's and Colitis
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-08-17
- Volume
- 16
- Issue
- 1
- Pages
- 27-38
- ISSN
- 1873-9946 (ISSN-L)
- 1876-4479
- OpenAlex
- W3195954854
- Cited by
- 178
- References
- 1
- FWCI
- 15.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial. https://app.cochat.ai/papers/10.1093/ecco-jcc/jjab133
- The paper
- Vermeire, S., D’Haens, G., Baert, F., Danese, S., Kobayashi, T., Loftus, E. V., Bhatia, S., Agboton, C., Rosario, M., Chen, C., Zhang, W., Kisfalvi, K., & Sandborn, W. J. (2022). Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial. Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jjab133
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.